$46.79
22.68% yesterday
Nasdaq, May 20, 09:48 pm CET
ISIN
US00973Y1082
Symbol
AKRO

Akero Therapeutics Inc Stock price

$47.57
+9.90 26.28% 1M
+16.94 55.28% 6M
+19.75 70.99% YTD
+27.43 136.20% 1Y
+38.60 430.32% 3Y
+23.22 95.36% 5Y
+31.57 197.31% 10Y
Nasdaq, Closing price Tue, May 20 2025
+9.43 24.72%
ISIN
US00973Y1082
Symbol
AKRO

Key metrics

Market capitalization $3.79b
Enterprise Value $3.14b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.50
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-306.35m
Free Cash Flow (TTM) Free Cash Flow $-262.63m
Cash position $686.29m
EPS (TTM) EPS $-3.75
P/E forward negative
Short interest 8.76%
Show more

Is Akero Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Akero Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Akero Therapeutics Inc forecast:

12x Buy
100%

Analyst Opinions

12 Analysts have issued a Akero Therapeutics Inc forecast:

Buy
100%

Financial data from Akero Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 0.02 0.02
75% 75%
-
-0.02 -0.02
75% 75%
-
- Selling and Administrative Expenses 40 40
20% 20%
-
- Research and Development Expense 266 266
56% 56%
-
-306 -306
50% 50%
-
- Depreciation and Amortization 0.02 0.02
75% 75%
-
EBIT (Operating Income) EBIT -306 -306
50% 50%
-
Net Profit -269 -269
50% 50%
-

In millions USD.

Don't miss a Thing! We will send you all news about Akero Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Akero Therapeutics Inc Stock News

Neutral
MarketBeat
8 days ago
The bear market induced by the Federal Reserve's monetary tightening officially ended in 2023, but it seems no one remembered to tell the biotech sector.
Neutral
GlobeNewsWire
9 days ago
Phase 2b SYMMETRY study preliminary results showed statistically significant reversal of compensated cirrhosis (F4) due to MASH following 96 weeks of treatment with efruxifermin (EFX)
Neutral
GlobeNewsWire
11 days ago
Analysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology response
More Akero Therapeutics Inc News

Company Profile

Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.

Head office United States
CEO Andrew Cheng
Employees 63
Founded 2017
Website www.akerotx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today